Azamian Bobak R. 4

What Happened

• Bobak R. Azamian, President, CEO and Board Chair of Tarsus Pharmaceuticals (TARS), sold a total of 10,000 shares via open‑market dispositions on June 17, 2026, generating approximately $615,489 in proceeds. The two reported lots were 4,582 shares at a weighted average price of $61.24 (≈ $280,602) and 5,418 shares at a weighted average price of $61.81 (≈ $334,887). These were sales (dispositions), not purchases.

Key Details

• Transaction dates: June 17, 2026.
• Reported weighted average prices and ranges:
  • 4,582 shares reported at $61.24 (actual sale prices in this lot ranged $60.51–$61.50 per footnote).
  • 5,418 shares reported at $61.81 (actual sale prices in this lot ranged $61.52–$62.13 per footnote).
• Total proceeds: ≈ $615,489.
• Method: Sales effected automatically under a Rule 10b5‑1 trading plan adopted by Mr. Azamian on December 9, 2025 (footnote).
• Capacity: Mr. Azamian reports these shares in his capacity as trustee of the Bobak Azamian Living Trust and has voting/dispositive power over them (footnote).
• Filing: Form 4 was filed June 22, 2026 reporting June 17 transactions (verify timeliness—Form 4s are generally due within two business days of the transaction).
• Filing code: Disposition code = S (sale). No purchases or derivative exercises in this filing.

Context

• These sales were made under a prearranged 10b5‑1 plan, which is a common way for insiders to sell shares on a preset schedule and is generally viewed as routine rather than a direct signal of sentiment.
• For retail investors: purchases by insiders typically attract more attention as potential bullish signals; sales under 10b5‑1 plans can reflect preplanned liquidity needs or diversification rather than a change in view on the company.
• For full detail (exact per‑trade prices, post‑transaction holdings), consult the complete Form 4 filing (Accession: 0001827672-26-000009).